###begin article-title 0
The Angio-Fibrotic Switch of VEGF and CTGF in Proliferative Diabetic Retinopathy
###end article-title 0
###begin p 1
Conceived and designed the experiments: EJK RG ROS. Performed the experiments: EJK. Analyzed the data: MWT. Contributed reagents/materials/analysis tools: MDD JCV. Wrote the paper: EJK ROS. Overall responsibility for the coordination of the study: EJK. Collection of vitreous samples: EJK MDD JCV. Performed laboratory experiments: EJK. Interpretation of results: EJK FAV MDD JCV NO IK CJV RG. Preparation of the first drafts of the manuscript: EJK. Optimization of CTGF-ELISA and measurement of CTGF in vitreous samples: FAV. Supervision of all statistics: MWT. Supply of reagents: NO. Supervision of the laboratory experiments: IK. Preparation of the last version of the manuscript and supervision of the preparation of the manuscript: CJV. Supervision of part of the laboratory experiments: RG. Design of the study: ROS RG. Overall supervision of data collection: ROS.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
In proliferative diabetic retinopathy (PDR), vascular endothelial growth factor (VEGF) and connective tissue growth factor (CTGF) cause blindness by neovascularization and subsequent fibrosis, but their relative contribution to both processes is unknown. We hypothesize that the balance between levels of pro-angiogenic VEGF and pro-fibrotic CTGF regulates angiogenesis, the angio-fibrotic switch, and the resulting fibrosis and scarring.
###end p 3
###begin title 4
Methods/Principal Findings
###end title 4
###begin p 5
###xml 63 71 <span type="species:ncbi:9606">patients</span>
###xml 520 528 <span type="species:ncbi:9606">patients</span>
###xml 537 545 <span type="species:ncbi:9606">patients</span>
###xml 853 861 <span type="species:ncbi:9606">patients</span>
VEGF and CTGF were measured by ELISA in 68 vitreous samples of patients with proliferative DR (PDR, N = 32), macular hole (N = 13) or macular pucker (N = 23) and were related to clinical data, including degree of intra-ocular neovascularization and fibrosis. In addition, clinical cases of PDR (n = 4) were studied before and after pan-retinal photocoagulation and intra-vitreal injections with bevacizumab, an antibody against VEGF. Neovascularization and fibrosis in various degrees occurred almost exclusively in PDR patients. In PDR patients, vitreous CTGF levels were significantly associated with degree of fibrosis and with VEGF levels, but not with neovascularization, whereas VEGF levels were associated only with neovascularization. The ratio of CTGF and VEGF was the strongest predictor of degree of fibrosis. As predicted by these findings, patients with PDR demonstrated a temporary increase in intra-ocular fibrosis after anti-VEGF treatment or laser treatment.
###end p 5
###begin title 6
Conclusions/Significance
###end title 6
###begin p 7
CTGF is primarily a pro-fibrotic factor in the eye, and a shift in the balance between CTGF and VEGF is associated with the switch from angiogenesis to fibrosis in proliferative retinopathy.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 129 132 129 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Aiello1">[1]</xref>
###xml 133 136 133 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Fong2">[4]</xref>
###xml 481 485 481 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">e.g.</italic>
###xml 680 683 679 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Hinton1">[5]</xref>
###xml 685 688 684 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Cui1">[6]</xref>
###xml 774 777 773 776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Aiello2">[7]</xref>
###xml 778 781 777 780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Gariano1">[9]</xref>
###xml 1124 1128 1123 1127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Kuiper1">[10]</xref>
###xml 1282 1286 1281 1285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Franklin1">[11]</xref>
###xml 1287 1291 1286 1290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-VanNieuwenhoven1">[15]</xref>
Blindness from proliferative diabetic retinopathy (PDR) is caused by angiogenesis and fibrosis in the vitreous cavity of the eye [1]-[4]. PDR is a wound healing-like response in which neovascularization is accompanied by influx of inflammatory cells and development of myofibroblasts. This progresses to a fibrotic phase with fibrovascular contraction causing haemorrhages, retinal detachment and inevitable blindness. Several growth factors have been shown to play a role in PDR, e.g. vascular endothelial growth factor-A (VEGF), transforming growth factor-ss, hepatocyte growth factor, platelet-derived growth factor, and the pro-fibrotic connective tissue growth factor (CTGF) [5], [6]. VEGF is considered to be the primary angiogenesis factor in this sequence of events [7]-[9]. In contrast, the causal factors of fibrosis and scarring and the regulation of the transition from angiogenesis to the fibrotic phase of PDR, which we propose to call the angio-fibrotic switch, remain largely unknown. We have recently shown that vitreous levels of CTGF correlate strongly with degree of fibrosis in vitreo-retinal disorders [10]. In other organs than the eye, CTGF has a similar role and has been identified as a potential therapeutic target for inhibition of pathological fibrosis [11]-[15].
###end p 9
###begin p 10
###xml 43 47 43 47 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-He1">[16]</xref>
###xml 48 52 48 52 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Kuiper2">[18]</xref>
###xml 128 132 128 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Inoki1">[19]</xref>
###xml 134 138 134 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Jang1">[20]</xref>
###xml 370 374 370 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Babic1">[21]</xref>
###xml 376 380 376 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Shimo1">[22]</xref>
###xml 478 482 478 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Watanabe1">[23]</xref>
###xml 569 573 569 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Hinton2">[24]</xref>
###xml 820 824 820 824 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Kuiper3">[25]</xref>
###xml 442 447 <span type="species:ncbi:9606">human</span>
###xml 529 537 <span type="species:ncbi:9606">patients</span>
###xml 732 736 <span type="species:ncbi:10090">mice</span>
Interestingly, CTGF is upregulated by VEGF [16]-[18] and inhibits VEGF-induced angiogenesis by formation of VEGF-CTGF complexes [19], [20], suggesting a negative feedback function of CTGF on VEGF-induced angiogenesis. In contrast, recombinant CTGF has been shown to cause angiogenesis in the cornea and in other in vivo models in addition to its pro-fibrotic properties [21], [22]. Other findings, such as co-localization of CTGF and VEGF in human subretinal neovascularization [23], and increased CTGF levels in vitreous of PDR patients with active neovascularization [24], also suggested that CTGF has a causal role in ocular neovascularization. However, we have recently challenged this concept by showing that in CTGF knock-out mice, angiogenesis is not impaired in several experimental models of neovascularization [25].
###end p 10
###begin p 11
###xml 452 460 <span type="species:ncbi:9606">patients</span>
###xml 575 580 <span type="species:ncbi:9606">human</span>
###xml 581 589 <span type="species:ncbi:9606">patients</span>
Based on these findings we propose a novel concept. We hypothesize that CTGF is a primary causal factor in sight-threatening fibrosis in the eye, and that an equilibrium shift in the balance between VEGF and CTGF levels in vitreous regulates the switch from the angiogenic phase to fibrosis in conditions such as PDR. Therefore, we investigated vitreous VEGF and CTGF levels in correlation with degree of fibrosis and neovascularization in a series of patients with PDR and other vitreoretinal disorders, and studied the effect of anti-VEGF treatment on the course of PDR in human patients.
###end p 11
###begin title 12
Methods
###end title 12
###begin title 13
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 13
###begin p 14
###xml 39 47 <span type="species:ncbi:9606">patients</span>
###xml 396 403 <span type="species:ncbi:9606">patient</span>
We investigated 68 vitreous samples of patients with PDR (N = 32), macular hole (N = 13) and idiopathic macular pucker (N = 23), who were operated by pars plana vitrectomy. The study was conducted according to the Declaration of Helsinki and approved by the institutional review board of the Academic Medical Center at the University of Amsterdam. Informed written consent was obtained from each patient.
###end p 14
###begin p 15
###xml 800 804 800 804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Aiello3">[26]</xref>
###xml 221 228 <span type="species:ncbi:9606">patient</span>
Clinical data, which allowed grading of fibrosis, activity of neovascularization, degree of haemorrhage, and presence and type of diabetes, were obtained from the pre-operative ophthalmic and ultrasound examinations, the patient files and from per-operative observations, using a standardized form. Fibrosis was graded as 0 when there was no fibrosis, as 1 when there were a few pre-retinal membranes (as limited as in macular pucker), as 2 when white pre-retinal fibrotic membranes with limited extension into the vitreous were present, and as 3 when abundant white membranes reaching into the vitreous body were observed. Neovascularization was graded as 0 when absent, as 1 (quiescent) when only non-perfused vessels were present, and as 2 (active) when there were perfused preretinal capillaries [26]. Degree of haemorrhage was graded as 0 when all media were clear and all fundus details were visible, as 1 when media were a little clouded but the fundus could still be examined, as 2 when the disk was obscured by haemorrhage, and as 3 when fundus details could not be obtained.
###end p 15
###begin p 16
###xml 96 104 <span type="species:ncbi:9606">patients</span>
###xml 122 129 <span type="species:ncbi:9606">patient</span>
In addition, we investigated retrospectively, after informed consent, the clinical records of 4 patients with PDR and one patient with proliferative retinopathy as a complication of branch retinal vein occlusion, who were treated with either pan-retinal photocoagulation (2 cases of PDR and the case of branch retinal vein occlusion) or with intravitreal injections with bevacizumab, an anti-VEGF agent, followed by pan-retinal laser treatment (2 cases of PDR).
###end p 16
###begin title 17
Sample collection
###end title 17
###begin p 18
Undiluted vitreous samples (0.5-1 ml) were obtained by using a vitrectome at the start of a classic three-port pars plana vitrectomy with the infusion line in position but not opened. The vitreous was transferred to sterile Eppendorf tubes and immediately frozen in dry ice. The samples were kept at -80degreesC until assayed.
###end p 18
###begin title 19
Measurement of CTGF and VEGF levels by enzyme-linked immunosorbent assays (ELISA)
###end title 19
###begin p 20
###xml 364 368 358 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Kuiper1">[10]</xref>
###xml 457 460 451 454 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 391 396 <span type="species:ncbi:9606">human</span>
After thawing, vitreous samples were centrifuged at 14.000 rpm for 15 minutes at 4degreesC, and supernatant was collected. Concentrations of CTGF were measured in samples by means of sandwich ELISAs, using two distinct monoclonal antibodies specifically recognizing the N-terminal part of the CTGF protein (FibroGen, San Francisco CA, USA) as described previously [10]. Purified recombinant human CTGF (FibroGen) was used as standard. Concentrations of VEGF165 were determined by means of sandwich ELISA according to the manufacturer's protocol (R&D Systems, Minneapolis MS, USA). All ELISAs were carried out in duplicate.
###end p 20
###begin title 21
Statistical analysis
###end title 21
###begin p 22
###xml 171 173 171 173 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sub>
###xml 675 677 675 677 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sub>
Both CTGF and VEGF levels were tested for normal distribution using the Shapiro-Wilk test (W>0.90). VEGF levels in vitreous showed a right skewed distribution and were log10 transformed to obtain a normal distribution. Associations between gender, age, diabetes type, degree of neovascularization, degree of haemorrhage and degree of fibrosis were assessed by ANOVA with correction for age and gender (included as covariates) where appropriate, and for unequal variances due to inter-assay variability. Least square means were estimated based on the model and, in case of an overall significant difference, compared using a post-hoc test. The correlation between CTGF and log10(VEGF) is expressed as Spearman correlation coefficient. In addition, univariate and multiple ordinal logistic regression analyses were performed with degree of fibrosis or neovascularization activity as dependent (outcome) variables. These effects were expressed as odds ratios with a 95% confidence interval. A two-tailed p-value <0.05 was considered statistically significant. All analyses were carried out using SAS (Version 9) software (SAS Institute, Cary NC, USA).
###end p 22
###begin title 23
Results
###end title 23
###begin title 24
###xml 16 24 <span type="species:ncbi:9606">patients</span>
Analysis of all patients
###end title 24
###begin p 25
###xml 83 90 83 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002675-t001">Table 1</xref>
###xml 306 308 306 308 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sub>
###xml 53 61 <span type="species:ncbi:9606">patients</span>
###xml 146 154 <span type="species:ncbi:9606">patients</span>
###xml 207 215 <span type="species:ncbi:9606">patients</span>
###xml 344 352 <span type="species:ncbi:9606">patients</span>
###xml 370 378 <span type="species:ncbi:9606">patients</span>
The research variables and characteristics of the 68 patients studied are shown in Table 1. There was a significant difference in age between the patients diagnosed with a macular hole or macular pucker and patients with PDR (66.4 versus 54.2, respectively; p = 0.001). Mean vitreous levels of CTGF and log10(VEGF) were significantly higher in patients with PDR than in patients diagnosed with a macular hole or macular pucker (p<0.001 for both growth factors, corrected for age (covariate)).
###end p 25
###begin title 26
###xml 26 34 <span type="species:ncbi:9606">patients</span>
Characteristics of the 68 patients included in the study.
###end title 26
###begin p 27
Abbreviations: PDR, proliferative diabetic retinopathy; SD, standard deviation; VEGF, vascular endothelial growth factor; CTGF, connective tissue growth factor.
###end p 27
###begin p 28
###xml 63 65 63 65 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sub>
###xml 183 185 183 185 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sub>
###xml 209 217 209 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002675-g001">Figure 1</xref>
###xml 471 473 471 473 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sub>
###xml 522 524 522 524 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sub>
###xml 723 725 723 725 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sub>
###xml 30 38 <span type="species:ncbi:9606">patients</span>
###xml 250 258 <span type="species:ncbi:9606">patients</span>
Univariate analysis of all 68 patients showed that CTGF and log10(VEGF) levels in vitreous correlated strongly (p<0.001). A scatter plot of the correlation between CTGF levels and log10(VEGF) levels is shown (Figure 1). Univariate analysis of all 68 patients also showed that levels of both growth factors were associated with diabetes-associated variables (i.e. the presence of diabetes, degree of neovascularization, fibrosis and haemorrhage; all p<0.001). CTGF and log10(VEGF) levels did not differ between genders. Log10(VEGF) levels were not associated with age, whereas CTGF levels were (p = 0.03). Multivariate analysis showed that mean CTGF levels were only associated with degree of fibrosis (p<0.001), whereas log10(VEGF) levels were only significantly associated with degree of neovascularization (p<0.001).
###end p 28
###begin title 29
###xml 46 48 46 48 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sub>
###xml 81 89 <span type="species:ncbi:9606">patients</span>
Correlation between the levels of CTGF and log10(VEGF) in the vitreous of all 68 patients.
###end title 29
###begin p 30
A significant (p = 0.01) Spearman's rank correlation (rho = 0.4) within all samples was found.
###end p 30
###begin title 31
###xml 12 20 <span type="species:ncbi:9606">patients</span>
Analysis of patients with PDR
###end title 31
###begin p 32
###xml 269 276 269 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002675-t001">Table 1</xref>
###xml 655 657 655 657 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sub>
###xml 779 787 779 787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002675-g001">Figure 1</xref>
###xml 850 852 850 852 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sub>
###xml 947 949 947 949 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sub>
###xml 1063 1071 1063 1071 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002675-g002">Figure 2</xref>
###xml 160 168 <span type="species:ncbi:9606">patients</span>
###xml 199 207 <span type="species:ncbi:9606">patients</span>
###xml 230 238 <span type="species:ncbi:9606">patients</span>
###xml 377 385 <span type="species:ncbi:9606">patients</span>
###xml 439 446 <span type="species:ncbi:9606">patient</span>
###xml 490 498 <span type="species:ncbi:9606">patients</span>
Most parameters which correlated with VEGF and CTGF levels were associated with diabetes (i.e. neovascularization, haemorrhage and fibrosis) in the group of 68 patients. However, the 13 macular hole patients and 23 macular pucker patients did not suffer from diabetes (Table 1). Therefore, to exclude this confounder, we repeated the statistical analysis on the data of the 32 patients with PDR who all had diabetes. Similar to the entire patient population, CTGF levels in the vitreous of patients with PDR were significantly associated with degree of fibrosis (p = 0.042), and not significantly with degree of neovascularization (p = 0.072), whereas log10(VEGF) levels were associated with degree of neovascularization (p = 0.011), and not with degree of fibrosis (p = 0.665) (Figure 1). We also evaluated the association between the ratio CTGF/log10(VEGF) and degree of fibrosis or degree of neovascularization, respectively. The ratio CTGF/log10(VEGF) was associated with degree of fibrosis (p = 0.009), but not with degree of neovascularization (p = 0.635) (Figure 2).
###end p 32
###begin title 33
###xml 89 91 89 91 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sub>
###xml 212 220 <span type="species:ncbi:9606">patients</span>
Mean levels of CTFG (A, D), geometric mean levels of VEGF (B, E), and mean ratio CTGF/log10(VEGF) (C, F) in relation with degree of neovascularization (A-C) and degree of fibrosis (D-F) in the vitreous of 32 PDR patients.
###end title 33
###begin p 34
Vertical bars represent 95% confidence intervals. Significant differences between groups are indicated.
###end p 34
###begin p 35
###xml 53 55 53 55 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sub>
###xml 168 170 168 170 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sub>
The Spearman correlation coefficient for CTGF and log10(VEGF) levels was 0.4 (p = 0.01). Age, gender, degree of haemorrhage did not show an association with CTGF or log10(VEGF) levels (p>0.05).
###end p 35
###begin p 36
###xml 241 248 241 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002675-t002">Table 2</xref>
###xml 298 300 298 300 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sub>
###xml 386 388 386 388 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sub>
###xml 453 455 453 455 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sub>
In a separate analysis, an ordinal logistic regression model with degree of fibrosis as dependent (outcome) variable was used to sort out the strongest predictive variable for fibrosis. Univariate ordinal logistic regression model analysis (Table 2) showed that vitreous levels of CTGF and CTGF/log10(VEGF) ratios were associated with fibrosis. The association was not found between log10(VEGF) levels and degree of fibrosis but it was found between log10(VEGF) levels and degree of neovascularization.
###end p 36
###begin title 37
Odds ratio (OR) and 95% confidence interval (95%CI) of the univariate ordinal logistic regression models with degree of neovascularization or fibrosis as outcome in the PDR population (N = 32), respectively.
###end title 37
###begin p 38
###xml 48 50 48 50 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sub>
###xml 131 133 131 133 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sub>
###xml 209 219 209 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">positively</italic>
###xml 278 280 278 280 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sub>
###xml 303 311 303 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">negative</italic>
###xml 434 436 434 436 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sub>
In a multifactorial model with both CTGF and log10(VEGF) levels as predictors for degree of fibrosis, both CTGF (p = 0.008) and log10(VEGF) (p = 0.033) were associated with degree of fibrosis: CTGF associated positively with an odds ratio of 1.19 (95% CI: 1.05-1.36) whereas log10(VEGF) levels showed a negative association with an odds ratio of 0.06 (95% CI: 0.01-0.80). These findings explain the strong association between CTGF/log10(VEGF) ratios and fibrosis in the univariate analysis.
###end p 38
###begin title 39
Clinical course of proliferative retinopathy after laser or anti-VEGF treatment
###end title 39
###begin p 40
###xml 238 246 238 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002675-g003">Figure 3</xref>
###xml 489 497 489 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002675-g004">Figure 4</xref>
In each of the 4 cases of PDR, we observed a transition from pre-retinal angiogenesis to a temporary phase of progressing pre-retinal fibrosis after pan-retinal laser treatment, or after anti-VEGF treatment followed by pan-retinal laser (Figure 3). In the case of branch retinal vein occlusion complicated by local pre-retinal angiogenesis with leaky vessels due to ischemia, the new vessels stopped growing and did not leak anymore after laser treatment, whereas fibrosis did not follow (Figure 4).
###end p 40
###begin title 41
###xml 24 31 <span type="species:ncbi:9606">patient</span>
Fundus photographs of a patient with proliferative diabetic retinopathy and new vessels (nv) along the lower vascular arcade, before (A) and 8 months after (B) an injection with bevacizumab followed by pan-retinal photocoagulation.
###end title 41
###begin p 42
Note the increase in fibrosis (f) after anti-VEGF and laser treatment (B).
###end p 42
###begin title 43
###xml 75 82 <span type="species:ncbi:9606">patient</span>
Fundus photographs (A, D) and fluorescein angiographic imaging (B, C) of a patient with branch retinal vein occlusion before (A-C) and after (D) treatment with pan-retinal photocoagulation.
###end title 43
###begin p 44
Note the leaky vessels consistent with angiogenesis(A, C), and the quiet aspect of the vessels after treatment without formation of fibrosis (D). n, normal; nv, neovascularization.
###end p 44
###begin title 45
Discussion
###end title 45
###begin p 46
The observations presented in this study, set against the background of existing literature on VEGF and CTGF, prompt us to propose a novel concept of the regulation of angiogenesis and fibrosis in ocular disease, and in wound healing in general. In this concept, angiogenesis in the vitreous is driven by VEGF, which amongst other factors upregulates the pro-fibrotic factor CTGF in various cell types in the newly formed neovascular membranes. Increasing levels of CTGF inactivate VEGF by reduction of production and complex formation, and when the equilibrium between these two factors shifts to a certain threshold ratio, the angio-fibrotic switch occurs and fibrosis driven by excess CTGF leads to scarring and blindness. This concept identifies CTGF as a major potential therapeutic target in the treatment of ocular fibrosis, in particular in combination with anti-VEGF agents.
###end p 46
###begin p 47
###xml 175 179 175 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Kuiper1">[10]</xref>
###xml 288 292 288 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Franklin1">[11]</xref>
###xml 293 297 293 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Perbal1">[13]</xref>
###xml 299 303 299 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Igarashi1">[27]</xref>
###xml 304 308 304 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Moussad1">[31]</xref>
###xml 409 413 409 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Babic1">[21]</xref>
###xml 415 419 415 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Shimo1">[22]</xref>
###xml 421 425 421 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Hinton2">[24]</xref>
###xml 427 431 427 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Kondo1">[32]</xref>
###xml 966 969 966 969 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Aiello2">[7]</xref>
###xml 971 974 971 974 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Witmer1">[8]</xref>
###xml 976 980 976 980 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Aiello3">[26]</xref>
###xml 982 986 982 986 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Frank1">[33]</xref>
###xml 987 991 987 991 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Hofman1">[35]</xref>
###xml 1082 1086 1082 1086 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Hughes1">[36]</xref>
###xml 1114 1118 1114 1118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Kuiper4">[37]</xref>
###xml 1174 1177 1174 1177 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 1199 1202 1199 1202 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1338 1342 1338 1342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Kuiper3">[25]</xref>
###xml 1783 1787 1783 1787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Spaide1">[38]</xref>
###xml 1788 1792 1788 1792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Avery1">[40]</xref>
###xml 466 471 <span type="species:ncbi:9606">human</span>
###xml 1070 1073 <span type="species:ncbi:10116">rat</span>
###xml 1229 1233 <span type="species:ncbi:10090">mice</span>
###xml 1708 1716 <span type="species:ncbi:9606">patients</span>
###xml 1831 1839 <span type="species:ncbi:9606">patients</span>
What is the evidence that this concept may be true? We have previously shown that vitreous CTGF levels strongly correlate with degree of fibrosis in vitreo-retinal conditions [10], an observation which is in line with the established role of CTGF in pathological fibrosis in other organs [11]-[13], [27]-[31]. However, exogenous CTGF has been reported to have angiogenic effects in ocular experimental models [21], [22], [24], [32]. The present study shows that, in human PDR, the CTGF levels and the ratio of CTGF over VEGF are strongly associated with the presence and degree of fibrosis, whereas CTGF levels, in contrast to VEGF levels, do not have an association with neovascularization. Moreover, multivariate analysis revealed that degree of fibrosis was best predicted by the ratio of CTGF over VEGF. VEGF levels do correlate significantly with active neovascularization, in agreement with the widely accepted role of VEGF as a major ocular angiogenic factor [7], [8], [26], [33]-[35]. We have previously shown that CTGF expression is induced by AGEs in diabetic rat retinas [36], particularly in pericytes [37]. We also have shown in various animal models using CTGF+/- heterozygous and CTGF-/- homozygous CTGF-deficient mice that diminished levels or even complete absence of CTGF did not affect neovascularization significantly [25]. These findings support our concept as outlined above. Our findings question the applicability of the concept of CTGF-driven angiogenesis to in vivo ocular disease. Rather, the accumulated evidence indicates that CTGF effects are highly context dependent and, in the specific condition of PDR, cause fibrosis rather than angiogenesis. Observations by others in PDR patients after VEGF inhibition by intravitreal injections with bevacizumab [38]-[40] may sustain this assumption. In these patients, a remarkable inhibition of angiogenesis is observed. We like to suggest that elevated CTGF levels, which remain in the vitreous after VEGF inhibition, are not able to maintain the angiogenic response, providing further evidence that CTGF has no pro-angiogenic role in PDR.
###end p 47
###begin p 48
###xml 417 420 417 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Witmer1">[8]</xref>
###xml 603 606 603 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Aiello1">[1]</xref>
###xml 608 611 608 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Fong1">[3]</xref>
###xml 613 616 613 616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Fong2">[4]</xref>
###xml 618 621 618 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Gariano1">[9]</xref>
PDR and other proliferative retinopathies, which represent important causes of blindness, are caused by widespread retinal ischemia. In these conditions, pre-retinal neovascularization into the vitreous is the first sign that a fibrovascular wound healing reaction will develop in later stages. VEGF produced by the ischemic retina is considered to be the major causal growth factor in the neovascularization process [8]. In later stages of PDR, scarring mechanisms within the fibrovascular membranes become more important, and fibrosis and vitreoretinal traction cause retinal detachment and blindness [1], [3], [4], [9]. The mechanisms causing this transition, the angio-fibrotic switch, have not been elucidated.
###end p 48
###begin p 49
###xml 115 117 115 117 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sub>
###xml 405 409 405 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-He1">[16]</xref>
###xml 411 415 411 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Suzuma1">[17]</xref>
###xml 446 450 446 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Kuiper2">[18]</xref>
###xml 452 456 452 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Hughes1">[36]</xref>
###xml 714 718 714 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Inoki1">[19]</xref>
###xml 720 724 720 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Jang1">[20]</xref>
###xml 726 730 726 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Hashimoto1">[41]</xref>
###xml 799 803 799 803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Chang1">[42]</xref>
###xml 956 960 956 960 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-VanNieuwenhoven1">[15]</xref>
###xml 962 966 962 966 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Yokoi1">[43]</xref>
###xml 976 980 976 980 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Mori1">[30]</xref>
###xml 1014 1018 1014 1018 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Kita1">[44]</xref>
###xml 20 25 <span type="species:ncbi:9606">human</span>
###xml 427 430 <span type="species:ncbi:10116">rat</span>
###xml 1099 1107 <span type="species:ncbi:9606">patients</span>
###xml 1278 1286 <span type="species:ncbi:9606">patients</span>
Further analysis of human vitreous samples in our study demonstrated a significant correlation between CTGF and log10(VEGF) levels. This may relate to the fact that VEGF and CTGF are both direct targets of factors such as glucose and AGEs, inherent to the diabetic condition. It may also reflect that VEGF induces CTGF expression in the eye, as has been demonstrated in retinal endothelial cells in vitro [16], [17] and in the rat retina in vivo [18], [36]. The consequent rise of the ratio of CTGF over VEGF may contribute to the angio-fibrotic shift occurring during progression of PDR: it has been reported that CTGF can influence VEGF availability on different levels, including direct protein-protein binding [19], [20], [41] and degradation of HIF-1a, which is a transcription factor for VEGF [42]. Angiogenesis may thus decline due to inactivation of VEGF by CTGF. Subsequent fibrosis may be induced by excess of unbound CTGF as was found in kidney [15], [43] and skin [30]. An earlier study by Kita et al. [44] did not show a significant correlation between CTGF and VEGF in the vitreous of patients with PDR and proliferative vitreoretinopathy. The reason for the difference with the current results is unknown, but may lie in the fact that we analyzed vitreous of PDR patients only.
###end p 49
###begin p 50
###xml 371 375 371 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Hoshijima1">[45]</xref>
###xml 376 380 376 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Nishida1">[47]</xref>
###xml 500 503 500 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Hinton1">[5]</xref>
###xml 505 508 505 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Cui1">[6]</xref>
Our observations that vitreous VEGF levels were significantly higher in active neovascularization than in quiescent neovascularization, and were negatively associated to degree of fibrosis, support this concept. It may, however, not be ruled out that other factors such as fibronectin, integrins and proteoglycans have an influence on the bioavailability of CTGF as well [45]-[47]. Furthermore, several growth factors have been suggested to play a role in angiogenesis and fibrosis in ocular disease [5], [6], which may also have influence on the presence and availability of VEGF and/or CTGF.
###end p 50
###begin p 51
###xml 660 664 660 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Aiello3">[26]</xref>
###xml 161 168 <span type="species:ncbi:9606">patient</span>
###xml 389 397 <span type="species:ncbi:9606">patients</span>
###xml 680 688 <span type="species:ncbi:9606">patients</span>
###xml 806 813 <span type="species:ncbi:9606">patient</span>
Our findings suggest that the balance between VEGF and CTGF determines the angio-fibrotic switch. This concept predicts that a sharp decline of VEGF levels in a patient with active neovascularization due to PDR inhibits angiogenesis, cause the angio-fibrotic switch and temporarily increase fibrosis. In a non-systematic survey, we studied the clinical files of a small series of four PDR patients with active neovascularization treated with intravitreal bevacizumab, an anti-VEGF antibody, and/or pan-retinal laser. Pan-retinal photocoagulation is a therapy which destroys large areas of retina, and which is known to markedly reduce intra-ocular VEGF levels [26]. In these four patients, we did indeed observe regression of neovascularization and the predicted temporary increase in fibrosis. In another patient with branch retinal vein occlusion complicated by focal pre-retinal neovascularization, fibrosis did not follow laser treatment. This suggests that for the angio-fibrotic switch to occur, CTGF levels need to reach a threshold value and a sufficient number of target cells must be able to elicit the fibrotic response. Therefore, intra-ocular fibrosis appears to be a tightly regulated on-off response, like intra-ocular angiogenesis.
###end p 51
###begin p 52
###xml 152 156 152 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Franklin1">[11]</xref>
###xml 157 161 157 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Perbal1">[13]</xref>
###xml 163 167 163 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-VanNieuwenhoven1">[15]</xref>
###xml 169 173 169 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Igarashi1">[27]</xref>
###xml 174 178 174 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Moussad1">[31]</xref>
###xml 180 184 180 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Yokoi1">[43]</xref>
###xml 186 190 186 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Frazier1">[48]</xref>
###xml 191 195 191 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Yokoi2">[50]</xref>
###xml 231 235 231 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Kuiper1">[10]</xref>
###xml 237 241 237 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-He2">[51]</xref>
###xml 333 337 333 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-He1">[16]</xref>
###xml 338 342 338 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Kuiper2">[18]</xref>
###xml 451 455 451 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Watanabe1">[23]</xref>
###xml 531 535 531 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Watanabe1">[23]</xref>
###xml 752 756 752 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Hinton2">[24]</xref>
###xml 771 775 771 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Kuiper4">[37]</xref>
###xml 1031 1035 1031 1035 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002675-Kita1">[44]</xref>
###xml 409 417 <span type="species:ncbi:9606">patients</span>
###xml 668 676 <span type="species:ncbi:9606">patients</span>
###xml 693 698 <span type="species:ncbi:9606">human</span>
###xml 887 892 <span type="species:ncbi:9606">human</span>
###xml 1007 1012 <span type="species:ncbi:9606">human</span>
Existing literature supports our general concept. The role of CTGF as pro-fibrotic factor is well-established in various organs such as skin and kidney [11]-[13], [15], [27]-[31], [43], [48]-[50] and recently in the retina as well [10], [51]. Furthermore, mRNA and protein of CTGF is upregulated by VEGF in retinal endothelial cells [16]-[18] and co-localizes with VEGF in neovascular subretinal membranes of patients with age-related macular disease [23]. In these membranes, CTGF is localized in retinal pigment epithelial cells [23], which are capable of transdifferentiation into myofibroblasts, the major cell type driving fibrosis. In fibrovascular membranes of patients with PDR and in human diabetic retina, CTGF is localized in myofibroblasts [24] and pericytes [37] which can also transform into myofibroblasts. Finally, in a recent study, it was not only shown that activated human hyalocytes and Muller cells produce CTGF, but also that CTGF does not induce pro-angiogenic functions in cultured human endothelial cells [44].
###end p 52
###begin p 53
In summary, our results suggest that, in contrast to VEGF, elevated CTGF levels do not significantly contribute to ocular angiogenesis in PDR. In addition, we propose that CTGF, in a critical balance with VEGF, drives the angio-fibrotic switch and subsequent fibrosis in PDR. This indicates that CTGF-targeted therapy is a possible novel option to prevent sight-threatening fibrosis in PDR and other ocular diseases that are associated with neovascularization and fibrosis. Our concept of the regulation of the angio-fibrotic switch may also apply to wound healing processes outside the eye.
###end p 53
###begin title 54
References
###end title 54
###begin article-title 55
Diabetic retinopathy.
###end article-title 55
###begin article-title 56
Pathogenesis of proliferative vitreoretinopathy.
###end article-title 56
###begin article-title 57
Diabetic retinopathy.
###end article-title 57
###begin article-title 58
Diabetic retinopathy.
###end article-title 58
###begin article-title 59
Novel growth factors involved in the pathogenesis of proliferative vitreoretinopathy.
###end article-title 59
###begin article-title 60
Stage specificity of novel growth factor expression during development of proliferative vitreoretinopathy.
###end article-title 60
###begin article-title 61
Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor.
###end article-title 61
###begin article-title 62
Vascular endothelial growth factors and angiogenesis in eye disease.
###end article-title 62
###begin article-title 63
Retinal angiogenesis in development and disease.
###end article-title 63
###begin article-title 64
###xml 95 100 <span type="species:ncbi:9606">human</span>
Association of connective tissue growth factor with fibrosis in vitreoretinal disorders in the human eye.
###end article-title 64
###begin article-title 65
Therapeutic approaches to organ fibrosis.
###end article-title 65
###begin article-title 66
Connective tissue growth factor: just another factor in renal fibrosis?
###end article-title 66
###begin article-title 67
CCN proteins: multifunctional signalling regulators.
###end article-title 67
###begin article-title 68
###xml 27 32 <span type="species:ncbi:9606">human</span>
###xml 103 111 <span type="species:ncbi:9606">patients</span>
Safety and tolerability of human monoclonal antibody FG-3019, anti-connective tissue growth factor, in patients with idiopathic pulmonary fibrosis.
###end article-title 68
###begin article-title 69
Imbalance of growth factor signalling in diabetic kidney disease: is connective tissue growth factor (CTGF, CCN2) the perfect intervention point?
###end article-title 69
###begin article-title 70
A role for connective tissue growth factor in the pathogenesis of choroidal neovascularization.
###end article-title 70
###begin article-title 71
Vascular endothelial growth factor induces expression of connective tissue growth factor via KDR, Flt1, and phosphatidylinositol 3-kinase-akt-dependent pathways in retinal vascular cells.
###end article-title 71
###begin article-title 72
Effect of VEGF-A on expression of pro-fibrotic growth factor and extracellular matrix genes in the retina.
###end article-title 72
###begin article-title 73
Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis.
###end article-title 73
###begin article-title 74
A novel ex vivo angiogenesis assay based on electroporation-mediated delivery of naked plasmid DNA to skeletal muscle.
###end article-title 74
###begin article-title 75
###xml 7 12 <span type="species:ncbi:10090">mouse</span>
Fisp12/mouse connective tissue growth factor mediates endothelial cell adhesion and migration through integrin alphavbeta3, promotes endothelial cell survival, and induces angiogenesis in vivo.
###end article-title 75
###begin article-title 76
Connective tissue growth factor induces the proliferation, migration, and tube formation of vascular endothelial cells in vitro, and angiogenesis in vivo.
###end article-title 76
###begin article-title 77
Expression of connective tissue growth factor and its potential role in choroidal neovascularization.
###end article-title 77
###begin article-title 78
###xml 94 102 <span type="species:ncbi:9606">patients</span>
Accumulation of NH(2)-terminal fragment of connective tissue growth factor in the vitreous of patients with proliferative diabetic retinopathy.
###end article-title 78
###begin article-title 79
###xml 81 85 <span type="species:ncbi:10090">mice</span>
Angiogenesis is not impaired in connective tissue growth factor (CTGF)-knock out mice.
###end article-title 79
###begin article-title 80
###xml 54 62 <span type="species:ncbi:9606">patients</span>
Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.
###end article-title 80
###begin article-title 81
###xml 123 131 <span type="species:ncbi:9606">patients</span>
Significant correlation between connective tissue growth factor gene expression and skin sclerosis in tissue sections from patients with systemic sclerosis.
###end article-title 81
###begin article-title 82
Connective tissue growth factor gene expression in tissue sections from localized scleroderma, keloid, and other fibrotic skin disorders.
###end article-title 82
###begin article-title 83
Connective tissue growth factor: a mediator of TGF-beta action on fibroblasts.
###end article-title 83
###begin article-title 84
###xml 119 124 <span type="species:ncbi:10090">mouse</span>
Role and interaction of connective tissue growth factor with transforming growth factor-beta in persistent fibrosis: A mouse fibrosis model.
###end article-title 84
###begin article-title 85
Connective tissue growth factor: what's in a name?
###end article-title 85
###begin article-title 86
Connective tissue growth factor increased by hypoxia may initiate angiogenesis in collaboration with matrix metalloproteinases.
###end article-title 86
###begin article-title 87
Vascular endothelial growth factor-its role in retinal vascular proliferation.
###end article-title 87
###begin article-title 88
Role of vascular permeability factor/vascular endothelial growth factor in eye disease.
###end article-title 88
###begin article-title 89
VEGF-A induced hyperpermeability of blood-retinal barrier endothelium in vivo is predominantly associated with pinocytotic vesicular transport and not with formation of fenestrations. Vascular endothelial growth factor-A.
###end article-title 89
###begin article-title 90
Advanced glycation end products cause increased CCN family and extracellular matrix gene expression in the diabetic rodent retina.
###end article-title 90
###begin article-title 91
###xml 93 98 <span type="species:ncbi:9606">human</span>
Differential expression of connective tissue growth factor in microglia and pericytes in the human diabetic retina.
###end article-title 91
###begin article-title 92
Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage.
###end article-title 92
###begin article-title 93
Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy.
###end article-title 93
###begin article-title 94
Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.
###end article-title 94
###begin article-title 95
Matrix metalloproteinases cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165.
###end article-title 95
###begin article-title 96
Effect of connective tissue growth factor on hypoxia-inducible factor 1alpha degradation and tumor angiogenesis.
###end article-title 96
###begin article-title 97
Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitial fibrosis.
###end article-title 97
###begin article-title 98
Functional characteristics of connective tissue growth factor on vitreoretinal cells.
###end article-title 98
###begin article-title 99
CT domain of CCN2/CTGF directly interacts with fibronectin and enhances cell adhesion of chondrocytes through integrin alpha5beta1.
###end article-title 99
###begin article-title 100
A novel integrin alpha5beta1 binding domain in module 4 of connective tissue growth factor (CCN2/CTGF) promotes adhesion and migration of activated pancreatic stellate cells.
###end article-title 100
###begin article-title 101
CTGF/Hcs24, hypertrophic chondrocyte-specific gene product, interacts with perlecan in regulating the proliferation and differentiation of chondrocytes.
###end article-title 101
###begin article-title 102
Stimulation of fibroblast cell growth, matrix production, and granulation tissue formation by connective tissue growth factor.
###end article-title 102
###begin article-title 103
Connective tissue growth factor mediates transforming growth factor beta-induced collagen synthesis: down-regulation by cAMP.
###end article-title 103
###begin article-title 104
Role of connective tissue growth factor in profibrotic action of transforming growth factor-beta: a potential target for preventing renal fibrosis.
###end article-title 104
###begin article-title 105
Connective tissue growth factor as a mediator of intraocular fibrosis.
###end article-title 105
###begin p 106
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: Noelynn Oliver is an employee of Fibrogen Inc, Roel Goldschmeding has received research support grants from Fibrogen Inc.
###end p 106
###begin p 107
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This study was supported by grants from the Diabetes Fonds Nederland (grant 2001 042) and by the Edmond and Marianne Blaauw Fonds.
###end p 107

